At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02179 RECBIO-B
Noon Closed 09-30 10:06:07
4.405
+0.005
+0.11%
High4.405Low4.405Vol5.00K
Open4.405D1 Closing4.400Amplitude0.00%
Mkt Cap2.76BTradable Cap2.02BTotal Shares626.00M
T/O22.03KT/O Rate0.00%Tradable Shares458.09M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
RECBIO-B’s August HKEX Filing Shows Stable Share Capital and Full Public Float Compliance
Bulletin Express  ·  09-01
RECBIO-B’s August HKEX Filing Shows Stable Share Capital and Full Public Float Compliance
RECBIO Announces 2026 Departure of Executive Director Wei Qifang; Dr. Wang Ruwei Appointed as Authorised Representative
Bulletin Express  ·  08-25
RECBIO Announces 2026 Departure of Executive Director Wei Qifang; Dr. Wang Ruwei Appointed as Authorised Representative
Jiangsu Recbio Files Board, Committee Member Roster for Disclosure Duties
Reuters  ·  08-25
Jiangsu Recbio Files Board, Committee Member Roster for Disclosure Duties
Jiangsu Recbio Technology Co., - Wei Qifang Resigns as Executive Director
THOMSON REUTERS  ·  08-25
Jiangsu Recbio Technology Co., - Wei Qifang Resigns as Executive Director
Jiangsu Recbio Files Board, Board Committee Member List with Disclosure Roles
Reuters  ·  08-19
Jiangsu Recbio Files Board, Board Committee Member List with Disclosure Roles
RECBIO-B (02179) Announces Interim Results: Loss Narrows 37.82% to Approximately RMB 212 Million
Stock News  ·  08-19
RECBIO-B (02179) Announces Interim Results: Loss Narrows 37.82% to Approximately RMB 212 Million
Jiangsu Recbio Technology H1 Revenue RMB 47 Million
THOMSON REUTERS  ·  08-19
Jiangsu Recbio Technology H1 Revenue RMB 47 Million
RECBIO-B Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Consider Interim Dividend
Bulletin Express  ·  08-07
RECBIO-B Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Consider Interim Dividend
Jiangsu Recbio Schedules Board Meeting to Review Interim Results, Consider Dividend
Reuters  ·  08-07
Jiangsu Recbio Schedules Board Meeting to Review Interim Results, Consider Dividend
RECBIO-B (02179) Issues Profit Warning, Expects Interim Loss Attributable to Shareholders of 201-222 Million Yuan, Narrowing by Approximately 34.71% to 40.93% Year-on-Year
Stock News  ·  07-31
RECBIO-B (02179) Issues Profit Warning, Expects Interim Loss Attributable to Shareholders of 201-222 Million Yuan, Narrowing by Approximately 34.71% to 40.93% Year-on-Year
Recbio Projects 1H26 Net Loss to Narrow by up to 41%, Revenue Falls 99%
Bulletin Express  ·  07-31
Recbio Projects 1H26 Net Loss to Narrow by up to 41%, Revenue Falls 99%
Jiangsu Recbio Technology Co - Estimates H1 2026 Loss Attributable Narrowed 34.7%-40.9% to RMB 201.2 Mln-222.4 Mln
THOMSON REUTERS  ·  07-31
Jiangsu Recbio Technology Co - Estimates H1 2026 Loss Attributable Narrowed 34.7%-40.9% to RMB 201.2 Mln-222.4 Mln
Recbio Expects H1 Loss to Narrow to RMB 201.23-222.41 Million
Reuters  ·  07-31
Recbio Expects H1 Loss to Narrow to RMB 201.23-222.41 Million
RECBIO-B Announces NDA Acceptance for REC610 Shingles Vaccine; Reschedules HPV 9-Valent Filing
Bulletin Express  ·  07-23
RECBIO-B Announces NDA Acceptance for REC610 Shingles Vaccine; Reschedules HPV 9-Valent Filing
Jiangsu Recbio Technology Co - Company to Re-plan Timetable for Hpv Vaccine Marketing Application
THOMSON REUTERS  ·  07-23
Jiangsu Recbio Technology Co - Company to Re-plan Timetable for Hpv Vaccine Marketing Application
Jiangsu Recbio Says NMPA Accepts Filing for Rec610 Shingles Vaccine Approval
Reuters  ·  07-23
Jiangsu Recbio Says NMPA Accepts Filing for Rec610 Shingles Vaccine Approval
Insiders Who Purchased CN¥15.3m Of Jiangsu Recbio Technology Stock May Not Have Expected 11% Tumble
Simply Wall St.  ·  06-03
Insiders Who Purchased CN¥15.3m Of Jiangsu Recbio Technology Stock May Not Have Expected 11% Tumble
Recbio AGM: Shareholders Endorse 2025 Accounts, 2026 Budget and Seven Other Resolutions with 99.99% Approval
Bulletin Express  ·  05-28
Recbio AGM: Shareholders Endorse 2025 Accounts, 2026 Budget and Seven Other Resolutions with 99.99% Approval
Recbio Converts 141.95 Million Shares into H Shares, Optimising Capital Structure and Hong Kong Float
Bulletin Express  ·  05-05
Recbio Converts 141.95 Million Shares into H Shares, Optimising Capital Structure and Hong Kong Float
Recbio completes full circulation, lists 141,953,489 converted H shares in Hong Kong
Reuters  ·  04-30
Recbio completes full circulation, lists 141,953,489 converted H shares in Hong Kong

Introduction

Company Name.
RECBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Jiangsu Recbio Technology Co Ltd is a China-based company engaged in vaccine research and development. The Company is still in the research and development stage. The Company's vaccine pipeline includes recombinant human papillomavirus (HPV) 9-valent vaccine, novel adjuvanted recombinant HPV 9-valent vaccine, recombinant HPV bivalent (Types 16/18) vaccine, recombinant HPV bivalent (Types 6/11) vaccine, novel adjuvanted recombinant HPV quadrivalent vaccine, novel adjuvanted recombinant shingles vaccine, novel adjuvanted recombinant respiratory syncytial virus vaccine, recombinant metapneumovirus vaccine, recombinant human cytomegalovirus vaccine, recombinant bicomponent COVID-19 vaccine, recombinant hepatitis B virus vaccine, and others.
Issue price:
--